Dr Reddy's Laboratories (DRREDDY) Weekly Analysis
Price & Volume
The stock price rose by 6.59% this week, continuing an upward trend. Trading activity was notably high, with total volume more than doubling compared to the previous week. The price currently sits above both its 50-day and 200-day moving averages, which are the average closing prices over the last 50 and 200 trading days respectively.
Technicals
The asset concluded the week at 1317.1, reflecting a 6.59% increase. Moving Averages, which represent the average price over specific periods to smooth out noise, show both the 20-day and 50-day lines sloping upward. Momentum indicators like the RSI, which measures the speed and change of price movements, rose to 61.94, while the MACD, a trend-following indicator showing the relationship between two price averages, generated a bullish crossover. Bollinger Band width, a measure of volatility or price dispersion, increased to 12.32%. The current technical regime is characterized by rising momentum alongside expanding volatility.
Fundamentals
Dr Reddy's Laboratories has demonstrated significant long-term growth, with revenue achieving a 3-year CAGR of 14.86% (the annual rate of growth over three years). In the most recent period ending Dec 2025, revenue grew 4.4% YoY, though net profit declined 15.2% YoY. Profitability remains robust, with a TTM (trailing twelve months, a snapshot of the last year) EBITDA margin of 27.4% (earnings before interest, taxes, depreciation, and amortization as a percentage of revenue). The company maintains a healthy financial position, reflected in a net debt-to-EBITDA ratio of 0.5 (a measure of leverage indicating how many years of earnings are needed to pay off debt) as of Mar 2025. The stock currently trades at 23.7× PE (price-to-earnings ratio, comparing share price to earnings) and 3.5× PB (price-to-book ratio, comparing share price to book value).
News
On April 23, 2026, Dr. Reddy's Laboratories experienced a significant rally as the Nifty Pharma index rose, though reports indicated the company was still awaiting regulatory approval for a key near-term product trigger. By April 24, 2026, market sentiment shifted following the company's clarification regarding its semaglutide application in Canada. Consequently, shares declined as major financial institutions, including Goldman Sachs and Citi, downgraded the stock or adopted a more cautious outlook. These developments collectively impacted the company's market performance during the week, reflecting investor sensitivity to regulatory timelines and analyst revisions regarding the firm's growth prospects.
Events
Dr. Reddy’s Laboratories has confirmed that it is still awaiting regulatory approval from Health Canada for its Semaglutide Injection. The company continues to engage with the authority and will provide updates as material developments occur.
Dr. Reddy's Laboratories will announce its financial results for the quarter and full year ended March 31, 2026, on May 12, 2026. Shareholders can participate in the scheduled earnings call at 19:30 IST to discuss the company's performance.
Dr. Reddy’s Laboratories has issued a public notice regarding the loss of share certificates by its shareholders. This administrative update informs the market and stakeholders that the company is processing requests for the issuance of duplicate certificates.
The BSE has sought clarification from Dr. Reddy's Laboratories regarding a significant increase in trading volume on April 24, 2026.
Dr. Reddy's Laboratories clarified that it has not yet received Health Canada approval for its Semaglutide Injection, though it was issued Drug Identification Numbers on April 22, 2026. This update addresses market speculation regarding the status of this regulatory filing.
India Ratings and Research has affirmed Dr. Reddy's Laboratories' bank loan facilities at 'IND AA+/Stable/IND A1+' and assigned ratings to additional facilities. The rating reflects the company's strong market position, sustained healthy credit metrics, and adequate liquidity, despite challenges from US market price erosion and regulatory scrutiny.
Dr. Reddy's Laboratories will announce its financial results for the quarter and full year ended March 31, 2026, on May 12, 2026. Shareholders can participate in the scheduled earnings call at 19:30 IST to discuss the company's performance.
Dr. Reddy’s Laboratories has issued a public notice regarding the loss of share certificates by its shareholders. This administrative update informs the market and stakeholders that the company is processing requests for the issuance of duplicate certificates.
The BSE has sought clarification from Dr. Reddy's Laboratories regarding a significant increase in trading volume on April 24, 2026.
Dr. Reddy's Laboratories clarified that it has not yet received Health Canada approval for its Semaglutide Injection, though it was issued Drug Identification Numbers on April 22, 2026. This update addresses market speculation regarding the status of this regulatory filing.
India Ratings and Research has affirmed Dr. Reddy's Laboratories' bank loan facilities at 'IND AA+/Stable/IND A1+' and assigned ratings to additional facilities. The rating reflects the company's strong market position, sustained healthy credit metrics, and adequate liquidity, despite challenges from US market price erosion and regulatory scrutiny.
Weekly Snapshot
Highlights
- The stock price rose by 6.59% this week, marking three consecutive weeks of gains.
- Trading activity surged significantly, with total volume more than doubling compared to the previous week.
- Technical momentum indicators strengthened, as the MACD (a trend-following indicator showing the relationship between two price averages) generated a bullish crossover.
- The company clarified that it has not yet received Health Canada approval for its Semaglutide Injection.
- Shares declined toward the end of the week following analyst downgrades and the regulatory clarification.
What This Means
Dr. Reddy's Laboratories experienced a volatile week characterized by a strong price rally followed by a pullback. While technical indicators like the RSI (which measures the speed and change of price movements) and MACD showed positive momentum, market sentiment shifted after the company confirmed that regulatory approval for its Semaglutide Injection in Canada remains pending. This news, combined with downgrades from major financial institutions, led to a decline in share price despite the high trading volume observed earlier in the period.
Latest Quarter Info
In the quarter ending December 2025, the company demonstrated mixed financial performance. While revenue showed a modest year-over-year growth of approximately 4.4%, it experienced a slight contraction on a quarter-over-quarter basis. Profitability metrics faced more significant pressure, with net profit and earnings per share declining both sequentially and compared to the same period last year. Despite these headwinds, the firm maintained an operating margin of 22%, reflecting a stable underlying cost structure relative to its sales volume. The gap between revenue growth and bottom-line performance highlights the impact of current expense levels and tax obligations on overall profitability. These results indicate a period of operational consolidation, where the company is managing top-line stability while navigating challenges to net earnings growth.